Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice

BMC Neuroscience

Volumn 8, Issue , 2007, Pages

  Kukar, Thomas ^a   Prescott, Sonya ^a   Eriksen, Jason L ^a   Holloway, Vallie ^a   Murphy, M Paul ^b   Koo, Edward H ^c   Golde, Todd E ^a   Nicolle, Michelle M ^a,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FLURBIPROFEN; FORMIC ACID; WATER; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); DRUG DERIVATIVE; PEPTIDE FRAGMENT; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; FEMALE; HIPPOCAMPUS; LEARNING DISORDER; LONG TERM CARE; MAZE TEST; MOUSE; NONHUMAN; TEMPORAL LOBE; TRANSGENIC MOUSE; WORKING MEMORY; ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; BRAIN; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; ENCEPHALITIS; GENETICS; MEMORY DISORDER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SENILE PLAQUE; STEREOISOMERISM; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENCEPHALITIS; FEMALE; FLURBIPROFEN; LEARNING DISORDERS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; SENILE PLAQUES; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 34547884277     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-8-54     Document Type: Article

References (62)

1. Blennow K de Leon MJ Zetterberg H Alzheimer's disease The Lancet 368 9533 387-403 10.1016/S0140-6736(06)69113-7
2. Golde TE Eckman CB Younkin SG Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease Biochim Biophys Acta 2000 1502 1 172-187 10899442
3. Younkin SG The role of A beta 42 in Alzheimer's disease J Physiol Paris 1998 92 3-4 289-292 10.1016/S0928-4257(98)80035-1 9789825
4. Selkoe DJ Clearing the brain's amyloid cobwebs Neuron 2001 32 2 177-180 10.1016/S0896-6273(01)00475-5 11683988
5. Selkoe DJ Podlisny MB Deciphering the genetic basis of alzheimer's disease Annual Review of Genomics and Human Genetics 2002 3 1 67-99 10.1146/annurev.genom.3.022502.103022
6. Scheuner D Eckman C Jensen M Song X Citron M Suzuki N Bird TD Hardy J Hutton M Kukull W Larson E Levy-Lahad E Viitanen M Peskind E Poorkaj P Schellenberg G Tanzi R Wasco W Lannfelt L Selkoe D Younkin S Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease Nat Med 1996 2 8 864-870 10.1038/nm0896-864 8705854
7. Duff K Eckman C Zehr C Yu X Prada CM Perez-tur J Hutton M Buee L Harigaya Y Yager D Morgan D Gordon MN Holcomb L Refolo L Zenk B Hardy J Younkin S Increased amyloid-[beta]42(43) in brains of mice expressing mutant presenilin 1 Nature 1996 383 6602 710-713 10.1038/383710a0 8878479
8. Games D Adams D Alessandrini R Barbour R Borthelette P Blackwell C Carr T Clemens J Donaldson T Gillespie F Guido T Hagopian S Johnson-Wood K Khan K Lee M Leibowitz P Lieberburg I Little S Masliah E McConlogue L Montoya-Zavala M Mucke L Paganini L Penniman E Power M Schenk D Seubert P Snyder B Soriano F Tan H Vitale J Wadsworth S Wolozin B Zhao J Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein Nature 1995 373 6514 523-527 10.1038/ 373523a0 7845465
9. Iijima K Liu HP Chiang AS Hearn SA Konsolaki M Zhong Y Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: A potential model for Alzheimer's disease Proc Natl Acad Sci U S A 2004 101 17 6623-6628 404095 15069204 10.1073/pnas.0400895101
10. Greeve I Kretzschmar D Tschape JA Beyn A Brellinger C Schweizer M Nitsch RM Reifegerste R Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila J Neurosci 2004 24 16 3899-3906 10.1523/JNEUROSCI.0283-04.2004 15102905
11. Lleo A Greenberg SM Growdon JH Current pharmacotherapy for Alzheimer's disease Annu Rev Med 2006 57 513-533 10.1146/ annurev.med.57.121304.131442 16409164
12. Birks J Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 2006 CD005593 16437532
13. McShane R Areosa Sastre A Minakaran N Memantine for dementia Cochrane Database Syst Rev 2006 CD003154 16625572
14. Seltzer B Cholinesterase inhibitors in the clinical management of Alzheimer's disease: Importance of early and persistent treatment J Int Med Res 2006 34 4 339-347 16989488
15. Smith M Wells J Borrie M Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia Alzheimer Dis Assoc Disord 2006 20 3 133-137 10.1097/00002093-200607000-00002 16917181
16. Etminan M Gill S Samii A Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies BMJ 2003 327 7407 128 165707 12869452 10.1136/ bmj.327.7407.128
17. McGeer PL McGeer EG Inflammation and the degenerative diseases of aging Ann N Y Acad Sci 2004 1035 104-116 10.1196/annals.1332.007 15681803
18. Townsend KP Pratico D Novel therapeutic opportunities for Alzheimer's disease: Focus on nonsteroidal anti-inflammatory drugs FASEB J 2005 19 12 1592-1601 10.1096/fj.04-3620rev 16195368
19. Rogers J Kirby LC Hempelman SR Berry DL McGeer PL Kaszniak AW Zalinski J Cofield M Mansukhani L Willson P Kogan F Clinical trial of indomethacin in Alzheimer's disease Neurology 1993 43 8 1609 8351023
20. Scharf S Mander A Ugoni A Vajda F Christophidis N A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology 1999 53 1 197-201 10408559
21. Aisen PS Schafer KA Grundman M Pfeiffer E Sano M Davis KL Farlow MR Jin S Thomas RG Thal LJ Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial JAMA 2003 289 21 2819-2826 10.1001/jama.289.21.2819 12783912
22. van Gool WA Aisen PS Eikelenboom P Anti-inflammatory therapy in Alzheimer's disease: Is hope still alive? J Neurol 2003 250 7 788-792 10.1007/s00415-003-1146-5 12883918
23. McGeer PL McGeer EG NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies Neurobiol Aging 2006
24. Lim GP Yang F Chu T Chen P Beech W Teter B Tran T Ubeda O Ashe KH Frautschy SA Cole GM Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease J Neurosci 2000 20 15 5709-5714 10908610
25. Gasparini L Ongini E Wilcock D Morgan D Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease Brain Research Reviews 2005 48 2 400-408 10.1016/ j.brainresrev.2004.12.029 15850679
26. Prosperi C Scali C Barba M Bellucci A Giovannini MG Pepeu G Casamenti F Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat Int J Immunopathol Pharmacol 2004 17 3 317-330 15461866
27. Jantzen PT Connor KE DiCarlo G Wenk GL Wallace JL Rojiani AM Coppola D Morgan D Gordon MN Microglial Activation and beta -Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice J Neurosci 2002 22 6 2246-2254 11896164
28. Sung S Yang H Uryu K Lee EB Zhao L Shineman D Trojanowski JQ Lee VMY Pratico D Modulation of Nuclear Factor-{kappa}B Activity by Indomethacin Influences A{beta} Levels but Not A{beta} Precursor Protein Metabolism in a Model of Alzheimer's Disease Am J Pathol 2004 165 6 2197-2206 1618710 15579461
29. Weggen S Eriksen JL Das P Sagi SA Wang R Pietrzik CU Findlay KA Smith TE Murphy MP Bulter T Kang DE Marquez-Sterling N Golde TE Koo EH A subset of NSAIDs lower amyloidogenic A[beta]42 independently of cyclooxygenase activity Nature 2001 414 6860 212-216 10.1038/35102591 11700559
30. Eriksen JL Sagi SA Smith TE Weggen S Das P McLendon DC Ozols VV Jessing KW Zavitz KH Koo EH Golde TE NSAIDs and enantiomers of flurbiprofen target {gamma}-secretase and lower A{beta}42 in vivo J Clin Invest 2003 112 3 440-449 166298 12897211 10.1172/JCI200318162
31. Kukar T Murphy MP Eriksen JL Sagi SA Weggen S Smith TE Ladd T Khan MA Kache R Beard J Dodson M Merit S Ozols VV Anastasiadis PZ Das P Fauq A Koo EH Golde TE Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production Nat Med 2005 11 5 545-550 10.1038/nm1235 15834426
32. Sagi SA Weggen S Eriksen J Golde TE Koo EH The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of {kappa}B Kinase, and NF{kappa}B, Do Not Reduce Amyloid {beta}42 Production J Biol Chem 2003 278 34 31825-31830 10.1074/jbc.M303588200 12805355
33. Weggen S Eriksen JL Sagi SA Pietrzik CU Ozols V Fauq A Golde TE Koo EH Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid {beta}42 Production by Direct Modulation of {gamma}-Secretase Activity J Biol Chem 2003 278 34 31831-31837 10.1074/jbc.M303592200 12805356
34. Takahashi Y Hayashi I Tominari Y Rikimaru K Morohashi Y Kan T Natsugari H Fukuyama T Tomita T Iwatsubo T Sulindac Sulfide Is a Noncompetitive gamma -Secretase Inhibitor That Preferentially Reduces Abeta 42 Generation J Biol Chem 2003 278 20 18664-18670 10.1074/jbc.M301619200 12637581
35. Beher D Clarke EE Wrigley JDJ Martin ACL Nadin A Churcher I Shearman MS Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target {gamma}-Secretase at a Novel Site: EVIDENCE FOR AN ALLOSTERIC MECHANISM J Biol Chem 2004 279 42 43419-43426 10.1074/jbc.M404937200 15304503
36. Geisslinger G Lotsch J Menzel S Kobal G Brune K Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers Br J Clin Pharmacol 1994 37 4 392-394 8018462
37. Geisslinger G Muth-Selbach U Coste O Vetter G Schrodter A Schaible HG Brune K Tegeder I Inhibition of Noxious Stimulus-Induced Spinal Prostaglandin E2 Release by Flurbiprofen Enantiomers. A Microdialysis Study Journal of Neurochemistry 2000 74 5 2094-2100 10.1046/ j.1471-4159.2000.0742094.x 10800954
38. Morihara T Chu T Ubeda O Beech W Cole GM Selective inhibition of Abeta42 production by NSAID R-enantiomers Journal of Neurochemistry 2002 83 4 1009-1012 10.1046/j.1471-4159.2002.01195.x 12421374
39. Black S Wilcock, G.K., Hawworth, J., Hendrix, S., Zavitz, K., Christensen, D.b., M-H., Bass, S., Laughlin, M., and Swabb, E. Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Abeta42 lowering agent in mild Alzheimer's disease: Results of a 12-month phase 2 trial and 1-year follow on study Neurology 2006 66(Suppl2) A347
40. McDonald RJ White NM Parallel information processing in the water maze: evidence for independent memory systems involving dorsal striatum and hippocampus Behav Neural Biol 1994 61 3 260-270 10.1016/ S0163-1047(05)80009-3 8067981
41. Stackman RW Eckenstein F Frei B Kulhanek D Nowlin J Quinn JF Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment Exp Neurol 2003 184 1 510-520 10.1016/S0014-4886(03)00399-6 14637120
42. Quinn JF Bussiere JR Hammond RS Montine TJ Henson E Jones RE Stackman RW Jr. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice Neurobiol Aging 2007 28 2 213-225 10.1016/ j.neurobiolaging.2005.12.014 16448723
43. Westerman MA Cooper-Blacketer D Mariash A Kotilinek L Kawarabayashi T Younkin LH Carlson GA Younkin SG Ashe KH The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease J Neurosci 2002 22 5 1858-1867 11880515
44. Lesne S Koh MT Kotilinek L Kayed R Glabe CG Yang A Gallagher M Ashe KH A specific amyloid-beta protein assembly in the brain impairs memory Nature 2006 440 7082 352-357 10.1038/nature04533 16541076
45. Janus C Pearson J McLaurin J Mathews PM Jiang Y Schmidt SD Chishti MA Horne P Heslin D French J Mount HT Nixon RA Mercken M Bergeron C Fraser PE St George-Hyslop P Westaway D A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 2000 408 6815 979-982 10.1038/35050110 11140685
46. Morgan D Diamond DM Gottschall PE Ugen KE Dickey C Hardy J Duff K Jantzen P DiCarlo G Wilcock D Connor K Hatcher J Hope C Gordon M Arendash GW A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 2000 408 6815 982-985 10.1038/ 35050116 11140686
47. Arendash GW Gordon MN Diamond DM Austin LA Hatcher JM Jantzen P DiCarlo G Wilcock D Morgan D Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: Task specificity and correlations between Abeta deposition and spatial memory DNA Cell Biol 2001 20 11 737-744 10.1089/10445490152717604 11788052
48. Dodart JC Bales KR Gannon KS Greene SJ DeMattos RB Mathis C DeLong CA Wu S Wu X Holtzman DM Paul SM Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat Neurosci 2002 5 5 452-457 11941374
49. Kotilinek LA Bacskai B Westerman M Kawarabayashi T Younkin L Hyman BT Younkin S Ashe KH Reversible memory loss in a mouse transgenic model of Alzheimer's disease J Neurosci 2002 22 15 6331-6335 12151510
50. Lazarov O Robinson J Tang YP Hairston IS Korade-Mirnics Z Lee VM Hersh LB Sapolsky RM Mirnics K Sisodia SS Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice Cell 2005 120 5 701-713 10.1016/j.cell.2005.01.015 15766532
51. Costa DA Cracchiolo JR Bachstetter AD Hughes TF Bales KR Paul SM Mervis RF Arendash GW Potter H Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms Neurobiol Aging 2006 16730391
52. Leipold DD Kantoci D Murray ED Jr. Quiggle DD Wechter WJ Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey Chirality 2004 16 6 379-387 10.1002/chir.20053 15190583
53. Wallace JL Muscara MN de Nucci G Zamuner S Cirino G del Soldato P Ongini E Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative, NCX-2216
54. Thomas T Nadackal TG Thomas K Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation Neuroreport 2001 12 15 3263-3267 10.1097/00001756-200110290-00024 11711868
55. Hirohata M Ono K Naiki H Yamada M Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's [beta]-amyloid fibrils in vitro Neuropharmacology 2005 49 7 1088-1099 10.1016/ j.neuropharm.2005.07.004 16125740
56. Sastre M Dewachter I Rossner S Bogdanovic N Rosen E Borghgraef P Evert BO Dumitrescu-Ozimek L Thal DR Landreth G Walter J Klockgether T van Leuven F Heneka MT Nonsteroidal anti-inflammatory drugs repress {beta}-secretase gene promoter activity by the activation of PPAR{gamma} PNAS 2006 103 2 443-448 1326151 16407166 10.1073/pnas.0503839103
57. Hsiao K Chapman P Nilsen S Eckman C Harigaya Y Younkin S Yang F Cole G Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice Science 1996 274 5284 99-103 10.1126/science.274.5284.99 8810256
58. McGowan E Pickford F Kim J Onstead L Eriksen J Yu C Skipper L Murphy MP Beard J Das P Jansen K Delucia M Lin WL Dolios G Wang R Eckman CB Dickson DW Hutton M Hardy J Golde T Abeta42 is essential for parenchymal and vascular amyloid deposition in mice Neuron 2005 47 2 191-199 1373682 16039562 10.1016/j.neuron.2005.06.030
59. Garcia MF Gordon MN Hutton M Lewis J McGowan E Dickey CA Morgan D Arendash GW The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice Neuroreport 2004 15 1 73-77 10.1097/00001756-200401190-00015 15106834
60. Gallagher M Burwell R Burchinal M Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze Behav Neurosci 1993 107 4 618-626 10.1037/ 0735-7044.107.4.618 8397866
61. Levites Y Das P Price RW Rochette MJ Kostura LA McGowan EM Murphy MP Golde TE Anti-A{beta}42- and anti-A{beta}40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model J Clin Invest 2006 116 1 193-201 1307561 16341263 10.1172/JCI25410
62. Das P Smithson LA Price RW Holloway VM Levites Y Chakrabarty P Golde TE Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy J Neuroinflammation 2006 3 17 1559596 16872492 10.1186/1742-2094-3-17